Corcept Therapeutics Incorporated
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph K. Belanoff
- Full Time Employees
- 500
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 149 Commonwealth Drive Menlo Park CA United States of America 94025
- IPO Date
- Apr 14, 2004
- CIK
- 0001088856
- Website
- corcept.com
- Similar Companies
- Business
- Corcept Therapeutics Incorporated (Nasdaq: CORT) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes drugs modulating cortisol activity at the glucocorticoid receptor to treat severe metabolic, oncologic, psychiatric and endocrine disorders. The company markets Korlym (mifepristone), the first FDA-approved treatment for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery; Korlym is available through a limited network of specialty pharmacies with patient support programs including financial assistance. Corcept advances a pipeline of proprietary selective cortisol modulators, including relacorilant in Phase 3 for Cushing's syndrome (PDUFA target date December 30, 2025) and in Phase 3 ROSELLA trial combined with nab-paclitaxel for platinum-resistant ovarian cancer (PDUFA target date July 11, 2026), where it demonstrated improved progression-free and overall survival in October 2025 ASCO late-breaker data; nenocorilant in Phase 1b with nivolumab for solid tumors; and other candidates targeting antipsychotic-induced weight gain, NASH, triple-negative breast cancer, castration-resistant prostate cancer, endometrial cancer, cervical cancer and platinum-sensitive ovarian cancer post-PARP inhibitor progression. Founded in 1998 and headquartered in Redwood City, California, the company conducts operations primarily in the United States and pursues global regulatory submissions including in Europe. Recent developments include Q3 2025 revenue of $207.6 million versus $182.5 million in Q3 2024, lifted full-year 2025 revenue guidance, initiation of new BELLA trial arms for relacorilant plus nab-paclitaxel with bevacizumab in platinum-sensitive ovarian cancer and in endometrial cancer, a Phase 2 collaboration with Arcagy Research for relacorilant plus nab-paclitaxel in cervical cancer, an ongoing transition to a new specialty pharmacy for Korlym fulfillment, and expansion of over 30 studies across endocrinology, oncology, metabolism and neurology.
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm